Deal

REPLIGEN CORP acquires Spectrum, Inc. (Spectrum LifeSciences)

August 2017 Full acquisition Ready
01 Scorecard

The deal at a glance

Private-market deal
REPLIGEN CORP acquires Spectrum, Inc. (Spectrum LifeSciences)
Deal value
~$359 million ($120M cash + ~$239M in Repligen stock)
Sector
Filtration
Date
August 2017
VectorShift
Made on VectorShift

REPLIGEN CORP acquired Spectrum, Inc. (Spectrum LifeSciences) for ~$359 million ($120M cash + ~$239M in Repligen stock), a transaction completed in August 2017, structured as combination (cash plus stock).

Spectrum, Inc. (Spectrum LifeSciences) operates in Filtration, is based in Rancho Dominguez, California, USA, had revenue of about $40.2 million (2016). Acquisition of Spectrum, Inc., a maker of hollow-fiber (HF) filtration products and KrosFlo TFF systems plus the Spectra/Por dialysis line, in a transaction Repligen called pivotal. Spectrum recorded revenue of $40.2 million in 2016. The deal substantially expanded Repligen's filtration franchise and global commercial footprint.

Hunt called it 'a pivotal transaction for Repligen that meets all of our acquisition criteria and is a major step forward in building Repligen as a global leader in bioprocessing.'

Market-leading hollow-fiber filtration with strong revenue and customer base. Combined filtration portfolio (HF + flat-sheet TFF) and expanded commercial infrastructure. Repligen Filtration franchise

This is a pivotal transaction for Repligen that meets all of our acquisition criteria and is a major step forward in building Repligen as a global leader in bioprocessing.
Tony J. Hunt, President and CEO, Repligen
Spectrum has developed world-class products delivered with first-class customer service. Repligen has a proven track record of unlocking additional value and accelerating growth.
Roy Eddleman, Chairman and CEO, Spectrum
Advisors not disclosed

No advisory firms have been disclosed for this transaction.

See how VectorShift works for your firm

Request Demo